Beijing Xinbo Technology Trading Co., Ltd.

The principle of Iressa in treating lung cancer
Iressa (gefitinib) is a new type of small molecular weight tumor treatment drug. Its mechanism of action is mainly to block conduction by inhibiting autophosphorylation. Inhibit the proliferation of tumor cells and achieve targeted therapy. It is mainly suitable for the treatment of locally advanced or metastatic non-small cell lung cancer that has previously received chemotherapy. Previous chemotherapy treatments mainly referred to platinum and docetaxel treatments. The efficacy for patients with locally advanced or metastatic non-small cell lung cancer who have failed chemotherapy is established based on objective response rate indicators. There are no controlled studies showing clinical benefit in improving disease-related symptoms and extending survival.
Iressa has the best therapeutic effect on lung adenocarcinoma in non-smoking women
It should be noted that many doctors say that this drug is targeted at lung adenocarcinoma in non-smoking women. This is just the beginning. The results of the experiment spread over time. The specific mechanism is not clear to everyone. But in fact, I found that saying this just makes the speech more consistent with Chinese habits. The real focus is, adenocarcinoma, women, and non-smoking. Why do you say this? In fact, most Asian women smoke very little, and adenocarcinomas account for the majority of lung cancers in women, while squamous cell carcinomas account for the majority in men. So this sentence should have a focus. The first thing to emphasize is lung adenocarcinoma. Because among my many patients, there are more than a dozen people who have survived the longest after taking Iressa (all more than 10 years), and only one of them is male, and all of them have adenocarcinoma. The effect of squamous cell carcinoma is not good. Even taking Tarceva only lasted for a month. Therefore, lung adenocarcinoma is the most critical. In addition, some subsequent studies have found that the key to targeted drugs like Iressa is actually the patient's genetic mutation. The probability of adenocarcinoma mutation is high, and the probability of mutation is also high in women. So now large hospitals generally require patients to do genetic mutation testing, and then choose whether to use Iressa based on the results because AstraZeneca's Iressa is only available for one month. The cost of the test is approximately between 10% and 20% (depending on the number of test targets). The most common mutation is the mutation of the and site. If there is a mutation (positive), the effective rate of taking Iressa is more than that of chemotherapy, and the effect is even better than chemotherapy (this is the so-called first-line treatment).